Vitalii M Orlov

Vitalii M Orlov

Auto-generated profile, based on publicly available information

Vitalii M Orlov

Hematologist, Clinic of Hematology, National Military Medical Clinical Center “Main Military Clinical Hospital” , Kyiv, 01133

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2025 in Military Medicine
Verified
Journal Article
Closed access
SHSvitlana A Husieva
Svitlana A Husieva
GOGalyna V Osyodlo
Galyna V Osyodlo
IGIan P Goncharov
Ian P Goncharov
OAOlena Ya Antonyuk
Olena Ya Antonyuk
AHAndrii V Husiev
Andrii V Husiev
VCVlad Yu Cherevko
Vlad Yu Cherevko
Introduction: During the full-scale war in Ukraine, the number of military personnel suffering from combat injuries with the development of anemia significantly increased. The work aimed to generalize and study the clinical and hematological characteristics of anemia in service members who received gunshot and blast injuries during combat operations. Materials and Methods: We examined 264 servicemen within 6 months (main group). They took part in hostilities and received gunshot and shrapnel wounds accompanied by blood loss. The control group consisted of 87 practically healthy service members. Complete blood test was performed on an automatic hematology analyser ABX Micros ES 60 of the company Horiba ABX. We determined the level of ferritin using the enzyme immunoassay method ELISA, the concentration of serum iron using the photometric method, and C-reactive protein (CRP) using the immunoturbidimetric latex method (quantitatively). The studies’ results were processed using variational statistics. For each group of patients, the arithmetic mean (M), the standard deviation (Ϭ), and the error of the arithmetic mean (m) were calculated. We used the statistical processing package STATISTICA 10 (Statsoft Inc.). Results: Isolated injuries accounted for 50.89%, injuries to two or more anatomical areas—49.11%, injuries to limbs and large joints—30.6%, chest—14.66%, abdominal cavity—21.9%, and polytrauma—32.84%. All patients had blood loss, but its degree was not countable. The number of erythrocyte mass transfusions ranged from 2 to 7 (3.5 ± 0.7 on average). A total of 39.42% of victims were delivered in a severe condition, and 60.58% in a moderate condition. We divided the patients into the groups: 1st group (n = 60) where the blood was tested after in 1 month after injury, 2nd (n = 42)—2 months, 3rd (n = 37), 4th (n = 31), 5th (n = 26), and 6th (n = 24) in 3, 4, 5, and 6 months. We observed an initial increase in the number of leukocytes and platelets, and a decrease in the levels of erythrocytes, hemoglobin, MCV, and MCH, an increase in the absolute number of granulocytes and monocytes, and a decrease in the number of lymphocytes. In all, 7.9% of patients were diagnosed with severe anemia, 44.7% with moderate, and 40.4% with mild. The ferritin level exceeded the control group’s results almost three times, while the iron content in the blood serum was significantly reduced. The hemoglobin level did not normalize within six months in most service members with anemia (because of severity or complications of the injuries and multiple surgeries). The CRP was elevated for 6 months after injury. Correlation analysis confirmed a positive relationship between the level of hemoglobin, the number of leukocytes, and the level of CRP. Conclusions: We view combat anemia as more than a hematology issue. It needs prompt, coordinated care from various fields. Interventions may include blood transfusions, surgery, and correcting iron levels. We can decrease the concentration of pro-inflammatory cytokines through anti-inflammatory therapy. Additionally, possible adrenergic modulation can promote erythropoiesis.

27 November 2025 in Military Medicine
Verified
Journal Article
Closed access
PDPavlo O Dubovetskyi
Pavlo O Dubovetskyi
SHSvitlana A Husieva
Svitlana A Husieva
IGIan P Goncharov
Ian P Goncharov
VOVitalii M Orlov
Vitalii M Orlov
Wartime conditions present major challenges to the timely diagnosis and management of severe aplastic anemia (SAA). We describe 3 previously healthy military service members who developed idiopathic SAA during active duty. In all 3 patients, no chronic illnesses were documented in the medical records, and no specific toxin exposures or prior hepatitis were recorded. All experienced a gradual onset of cytopenias accompanied by hemorrhagic symptoms, initial misclassification as immune thrombocytopenia or myelodysplastic syndrome, and war-related delays to definitive therapy. Each required prolonged transfusion support and broad-spectrum antibiotics for neutropenic complications. Two patients received immunosuppressive therapy (antithymocyte globulin plus cyclosporine A) four to 5 months after diagnosis, while the youngest underwent urgent allogeneic bone marrow transplantation. Despite severe logistical constraints, all survived the acute phase but remained transfusion-dependent at discharge. These cases underscore the need to strengthen medical logistics and ensure early access to specialized hematologic care to improve SAA outcomes during wartime.